GlassScriptPhysician profile
Kathryn E Bachman
NPI 1225427040
$3,877.90
in general payments reported to CMS, 2019-2025
23 companies · $572 in 2025
The $572 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $640 · 2022: $1,073 · 2023: $713 · 2024: $879 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,164.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $988.01 | 2022-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $436.63 | 2021-2025 | Farxiga, Wainua |
| Pfizer INC. | $359.89 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $306.17 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.59 | 2021-2024 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $250.05 | 2021-2025 | Lifevest |
| Abbott Laboratories | $213.92 | 2021-2025 | Cardiomems |
| Janssen Pharmaceuticals, INC | $189.46 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $156.70 | 2021-2024 | Eliquis, Camzyos |
| Alnylam Pharmaceuticals INC. | $123.33 | 2023-2024 | Amvuttra, Onpattro |
| Regeneron Healthcare Solutions, INC. | $76.63 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $71.95 | 2021-2022 | |
| Amarin Pharma, INC. | $64.98 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $64.22 | 2021-2022 | |
| Esperion Therapeutics, INC. | $56.47 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $54.44 | 2022-2024 | Ozempic |
| Atricure, INC. | $49.13 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $38.88 | 2021-2022 | |
| Philips North America LLC | $30.64 | 2025 | Extended Holter |
| Kestra Medical Technology Services, INC. | $28.53 | 2025 | Assure Wcd |
| Ferring Pharmaceuticals INC. | $28.40 | 2025 | Euflexxa |
| Lexicon Pharmaceuticals, INC. | $22.78 | 2024 | |
| Boston Scientific Corporation | $16.10 | 2023 | Watchman Access System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Bachman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.